Center for Clinical Studies, 451 N. Texas Ave, Webster, TX 77598, USA.
Expert Rev Anti Infect Ther. 2014 Mar;12(3):283-7. doi: 10.1586/14787210.2014.880337. Epub 2014 Jan 23.
The treatment of recurrent herpes labialis remains a challenge in the 21st century. The virus is ubiquitous and there is no vaccine against the disease. Although recurrence episodes are usually of shorter duration than the primary episode, they are debilitating to patients and there is significant stigma associated with the disease. Acyclovir Lauriad(®) is a new topical agent that was approved by the US FDA in 2013 for the treatment of recurrent herpes labialis, which affects approximately 20-40% of the population worldwide. The drug is a muco-adhesive tablet, applied to the upper gum at the onset of prodromal symptoms. Utilizing Lauriad(®) technology, a biologically active compound traverses the mucous membrane to deliver a high concentration of acyclovir directly to the site of the herpes simplex virus infection. Data from a Phase III clinical trial shows that this may be a promising therapy for patients with recurrent herpes labialis.
治疗复发性唇疱疹在 21 世纪仍然是一个挑战。该病毒无处不在，目前尚无针对该疾病的疫苗。虽然复发期通常比原发性发作持续时间短，但对患者来说却是虚弱的，并且与该疾病相关的耻辱感非常严重。阿昔洛韦 Lauriad(®)是一种新的局部用药物，于 2013 年获得美国 FDA 批准，用于治疗复发性唇疱疹，这种疾病影响着全球约 20-40%的人口。该药物是一种粘膜粘附片剂，在出现前驱症状时在上牙龈上使用。利用 Lauriad(®)技术，一种生物活性化合物穿过粘膜，将高浓度的阿昔洛韦直接输送到单纯疱疹病毒感染部位。III 期临床试验数据表明，这可能是复发性唇疱疹患者的一种有前途的治疗方法。
